Double-Dose HIV drug may work with TB therapy
NCT ID NCT05630872
First seen Dec 08, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study tested whether taking a double dose of the HIV drug dolutegravir (50 mg twice daily) along with the TB drug rifapentine can keep HIV under control in people with both HIV and tuberculosis. Thirty adults with HIV and TB took part. The goal was to see if the higher dose is safe and maintains enough drug levels to suppress HIV while treating TB.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-ASSOCIATED TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Durban International CRS (Site # 11201)
Westridge, Durban RSA, 4091, South Africa
-
South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793)
Worcester, Western Province, 6850, South Africa
-
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802)
Bangkok, 6850, Thailand
-
University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792)
Mowbray, Cape Town, Western Cape, 7700, South Africa
Conditions
Explore the condition pages connected to this study.